-
China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab
•
China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National Science Center’s Institute of Health and Medicine and Hefei Afana Biotechnology Co., Ltd to establish a joint laboratory. The new lab will concentrate on advancing biotechnology innovation and translational medicine. Leveraging Core Competencies for Nucleic…
-
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
•
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for its potentially groundbreaking oncolytic virus product, MVR-C5252, which is under development to treat gliomas. This first-in-class product marks a significant step forward in the treatment of brain tumors. Global Context and PrecedenceIn June 2021, Japanese…
